Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Ifetroban in Idiopathic Pulmonary Fibrosis: NCT05571059 Clinical Landscape Report 2026
15 October 2026
NCT05571059 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Obeticholic acid in Metabolic Dysfunction Associated Steatohepatitis: NCT05573204 Clinical Landscape Report 2026
15 October 2026
NCT05573204 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Febuxostat in Hyperuricemia: NCT05574036 Clinical Landscape Report 2026
15 October 2026
NCT05574036 clinical landscape for Hyperuricemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Osivelotor in Anemia, Sickle Cell: NL-OMON53865 Clinical Landscape Report 2026
15 October 2026
NL-OMON53865 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Linafexor in Metabolic Dysfunction Associated Steatohepatitis: NCT05591079 Clinical Landscape Report 2026
15 October 2026
NCT05591079 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Gatuzosiran in Metabolic Dysfunction Associated Steatohepatitis: NCT05583344 Clinical Landscape Report 2026
15 October 2026
NCT05583344 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
AMMONIA N-13 in Anemia, Sickle Cell: NCT05583721 Clinical Landscape Report 2026
15 October 2026
NCT05583721 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Minocycline Hydrochloride in Cognitive Dysfunction: NCT05605366 Clinical Landscape Report 2026
15 October 2026
NCT05605366 clinical landscape for Cognitive Dysfunction: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pioglitazone Hydrochloride in Metabolic Dysfunction Associated Steatohepatitis: NCT05605158 Clinical Landscape Report 2026
15 October 2026
NCT05605158 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Marstacimab-hncq in Hemophilia B: NCT05611801 Clinical Landscape Report 2026
15 October 2026
NCT05611801 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vitamin E Nicotinicate in Metabolic Dysfunction Associated Steatohepatitis: NCT05616442 Clinical Landscape Report 2026
15 October 2026
NCT05616442 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Motixafortide in Anemia, Sickle Cell: NCT05618301 Clinical Landscape Report 2026
15 October 2026
NCT05618301 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.